2000 Update of recommendations for the use of tumor markers in breast and colorectal cancer: Clinical practice guidelines of the American Society of Clinical Oncology

Journal of Clinical Oncology

Volumn 19, Issue 6, 2001, Pages 1865-1878

  Bast R C , Jr ^a   Ravdin, P ^a   Hayes, D F ^a   Bates, S ^a   Fritsche H , Jr ^a   Jessup, J M ^a   Kemeny, N ^a   Locker, G Y ^a   Mennel, R G ^a   Somerfield, M R ^a  

^a AMERICAN SOCIETY OF CLINICAL ONCOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE ANTIBIOTIC AGENT; CA 15-3 ANTIGEN; CA 19-9 ANTIGEN; CA 27-29 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CATHEPSIN D; CYCLOPHOSPHAMIDE; DOXORUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; METHOTREXATE; ONCOPROTEIN; PREDNISONE; PROGESTERONE RECEPTOR; PROTEIN P53; RAS PROTEIN; SIALIC ACID; TAMOXIFEN; TAXANE DERIVATIVE; TRASTUZUMAB; TUMOR MARKER; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER SURVIVAL; CLINICAL PRACTICE; COLORECTAL CANCER; COST EFFECTIVENESS ANALYSIS; DRUG SENSITIVITY; HORMONAL THERAPY; MEDICAL SOCIETY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE;

EID: 0035868668     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/jco.2001.19.6.1865     Document Type: Article

References (118)

1. Postsurgical surveillance of colon cancer: Preliminary cost analysis of physician examination, carcinoembryonic antigen testing, chest x-ray, and colonoscopy
2. Recommended Colorectal Cancer Surveillance Guidelines by the American Society of Clinical Oncology
3. Value of postoperative surveillance after radical surgery for colorectal cancer
4. Ki-ras mutation and p53 overexpression predict the clinical behavior of colorectal cancer: A Southwest Oncology Group study
5. Prognostic significance of p53, chromosome 17 copy number, and DNA ploidy in non-metastasized colorectal carcinomas (stages IB and II)
6. Prognostic evaluation of DNA flow cytometric and histopathologic parameters of colorectal cancer
7. DNA index as a significant predictor of recurrence in colorectal cancer
8. Prognostic significance of the DNA index in a colorectal cancer
9. Prognostic significance of DNA ploidy and proliferation in 309 colorectal carcinomas as determined by two-color multiparametric DNA flow cytometry
10. Prognostic value of ploidy of primary tumor and nodal secondaries in colorectal cancers
11. Prognostic value of DNA ploidy patterns of colorectal adenocarcinoma: Univariate and multivariate analysis
12. The prognostic role of the DNA ploidy pattern in colorectal cancer analysis using paraffin-embedded tissue by an improved method
13. The role of multiploidy as unfavourable prognostic variable in colorectal cancer
14. Five-year prospective study of DNA tumor ploidy and colorectal cancer survival
15. Overexpression of ras is an independent prognostic factor in colorectal adenocarcinoma
16. Cell proliferation-related markers in colorectal liver metastases: Correlation with patient prognosis
17. Prognostic significance of proliferation activity, DNA-ploidy, p53 and Ki-ras point mutations in colorectal liver metastases
18. Biomarkers for predicting response to regional chemo-immunotherapy in liver metastases from colorectal carcinoma
19. Use of Truquant BR radioimmunoassay for early detection of breast cancer recurrence in patients with stage II and stage III disease
20. Outcomes of cancer treatment for technology assessment and cancer treatment guidelines
21. Comparison of the diagnostic accuracy of CA27.29 and CA15.3 in primary breast cancer
22. CA15-3, CASA, MSA, and TPS as diagnostic serum markers in breast cancer
23. Tumor marker utility grading system: A framework to evaluate clinical utility of tumor markers
24. Review of clinical studies of CA 27.29 in breast cancer management
25. Rapid and prognostically valid quantification of immunohistochemical reactions by immunohistometry of the most positive tumour focus: A prospective follow-up study on breast cancer using antibodies against MIB-1, PCNA, ER, and PR
26. Prognostic and predictive factors in breast cancer by immunohistochemical analysis
27. Comparison of immunohistochemical and biochemical measurement of steroid receptors in primary breast cancer: Evaluation of discordant findings
28. Hormonal receptors in mammary carcinoma: Comparison between quantitative and qualitative methods
29. Simultaneous immunohistochemical and biochemical hormone receptor assessment in breast cancer provides complementary prognostic information
30. Comparison of standardized immunohistochemical and biochemical assays for estrogen and progesterone receptors in breast carcinoma
31. Mapping of ER gene CpG island methylation-specific polymerase chain reaction
32. Heat shock proteins hsp27 and hsp70: Lack of correlation with response to tamoxifen and clinical course of disease in estrogen receptor-positive metastatic breast cancer: A Southwest Oncology Group study
33. Mapping and characterization of the functional domains responsible for the differential activity of the A and B isoforms of the human progesterone receptor
34. In breast cancer, amplification of the steroid receptor coactivator gene AIB 1 is correlated with estrogen and progesterone receptor positivity
35. Activation of the Src/p21ras/Erk pathway by progesterone receptor via cross-talk with estrogen receptor
36. Quantitation of progesterone receptor mRNA in breast carcinoma by branched DNA assay
37. Use of reverse transcription-polymerase chain reaction methodology to detect estrogen-regulated gene expression in small breast cancer specimens
38. Detection of oestrogen and progesterone receptor expression in breast tumors by semiquantitative PCR
39. Prevalence of estrogen receptor variant messenger RNAs in human breast cancer
40. Progesterone receptor variants found in breast cells repress transcription by wild-type receptors
41. Novel progesterone receptor variants in breast cancers and normal breast repress transcription by wild-type receptors
42. The pathophysiological role of estrogen receptor variants in human breast cancer
43. Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells
44. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer
45. Efficacy and safety of Herceptin (humanized anti-HER2 antibody) as a single agent in 222 women with HER2 overexpression who relapsed following chemotherapy for metastatic breast cancer
46. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment
47. Addition of Herceptin (humanized anti-HER2 antibody) to first line chemotherapy for HER2 overexpressing metastatic breast cancer (HER2+/MBC) markedly increases anticancer activity: A randomized multinational controlled phase III trial
48. Overall survival advantage to simultaneous chemotherapy plus the humanized anti-HER2 monoclonal antibody Herceptin in HER2-overexpressing metastatic breast cancer
49. Comparison of fluorescence in situ hybridization (FISH) and immunohistochemistry (IHC) in determining HER-2/neu status in breast cancer patients
50. Prognostic importance of c-erbB-2 expression in breast cancer
51. Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer
52. Prognostic significance of HER-2/neu oncoprotein expression in node-positive breast cancer: The influence of the pattern of immunostaining and adjuvant therapy
53. Prognostic and predictive relevance of c-erbB-2 and ras expression in node positive and negative breast cancer
54. c-erbB-2 expression and benefit from adjuvant chemotherapy and radiotherapy of breast cancer
55. Benefit of CMF treatment in lymph node-positive breast cancer overexpressing HER-2
56. c-erbB-2 expression and S-phase activity predict response to adjuvant therapy in women with node-positive early breast cancer
57. erbB2, p53, and adjuvant therapy interactions in node positive breast cancer
58. erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer
59. Initial report of the SWOG biological correlative study of c-erbB-2 expression as a predictor of outcome in a trial comparing adjuvant CAF T with tamoxifen alone
60. HER2 overexpression as a predictor of survival in a trial comparing adjuvant FAC and CMF in breast cancer
61. c-erbB-2 expression as a predictor of outcome in a randomized trial comparing adjuvant CMF vs. single agent epirubicin in stage I-II breast cancer patients
62. Predictive value of topoisomerase II alpha and other prognostic factors for epirubicin chemotherapy in advanced breast cancer
63. c-erbB-2 (HER-2/neu) protein and drug resistance in breast cancer patients treated with induction chemotherapy
64. No significant predictive value of c-erbB-2 or p53 expression regarding sensitivity to primary chemotherapy or radiotherapy in breast cancer
65. Overexpression of HER2 modulates bcl-2, bcl-XL, and tamoxifen-induced apoptosis in human MCF-7 breast cancer cells
66. Overexpression of c-erbB2 is an independent marker of resistance to endocrine therapy in advanced breast cancer
67. HER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer: A Southwest Oncology Group study
68. Expression of epidermal growth factor receptor and c-erbB2 during the development of tamoxifen resistance in human breast cancer
69. pS2 protein: A marker improving prediction of response to neoadjuvant tamoxifen in post-menopausal breast cancer patients
70. c-erbB2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases
71. Lack of interaction of tamoxifen (T) use and ErbB-2/HER-2/Neu (H) expression in CALGB 8541: A randomized adjuvant trial of three different doses of cyclophosphamide, doxorubicin and fluorouracil (CAF) in node-positive primary breast cancer (BC)
72. Overexpression of both p185c-erbB2 and p170mdr-1 renders breast cancer cells highly resistant to Taxol
73. HER2 overexpression and paclitaxel sensitivity in breast cancer: Therapeutic implications
74. HER-2/neu overexpression and clinical taxane sensitivity: A multivariate analysis in patients with metastatic breast cancer
75. HER-2/neu amplification and response to doxorubicin/paclitaxel (AT) in women with metastatic breast cancer
76. Circulating HER-2/neu predicts resistance to Taxol/Adriamycin in metastatic breast carcinoma: Preliminary results of a multicentric study
77. Assessing the clinical impact of prognostic factors: When is "statistically significant" clinically useful?
78. Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: Prognostic significance of erbB-2 protein overexpression in primary breast cancer
79. The long term prognostic significance of c-erbB-2 in primary breast cancer
80. c-erbB-2 and ras expression levels in breast cancer are correlated and show a co-operative association with unfavorable clinical outcome
81. c-erbB-2 oncoprotein detected by automated quantitative immunocytochemistry in breast carcinomas correlates with patients' overall and disease-free survival
82. The prognostic value of c-erbB2 in primary breast carcinomas: A study on 942 cases
83. Prognostic value of intratumoral microvessel density, a measure of tumor angiogenesis, in node-negative breast carcinoma: Results of a multiparametric study
84. Prognostic significance of c-erbB-2 oncogene in axillary node-negative breast cancer
85. Association of c-erbB2 protein overexpression with high rate of cell proliferation, increased risk of visceral metastasis, and poor long-term survival in breast cancer
86. Correlation between p53, c-erbB-2, and topoisomerase II alpha expression: DNA ploidy, hormonal receptor status and proliferation in 356 node-negative breast carcinomas - Prognostic implications
87. Prognostic significance of HER-2/neu expression in breast cancer and its relationship to other prognostic factors
88. p53 in node-negative breast carcinoma: An immunohistochemical study of epidemiologic risk factors, histologic features, and prognosis
89. Prognostic value of proliferating cell nuclear antigen and c-erbB-2 compared with conventional histopathological factors in breast cancer
90. Risk-group discrimination in node-negative breast cancer using invasion and proliferation markers: 6-Year median follow-up
91. HER-2/neu in node-negative breast cancer: Prognostic significance of overexpression influenced by the presence of in situ carcinoma
92. HER-2/neu oncogene protein and prognosis in breast cancer
93. p53 protein accumulation and response to adjuvant chemotherapy in premenopausal women with node-negative early breast cancer
94. Predicting outcome for patients with node negative breast cancer: A comparative study of the value of flow cytometry and cell image analysis for determination of DNA ploidy
95. Immunohistochemical expression of p53 and c-erbB-2 in breast carcinoma: Relation with epidemiologic factors, histologic features and prognosis
96. Analysis of p53 gene mutation by polymerase chain reaction-single strand conformation polymorphism provides independent prognostic information in nodenegative breast cancer
97. Clinical significance of HER-2/neu oncogene amplification in primary breast cancer: The South Australian Breast Cancer Study Group
98. neu/erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer: Toronto Breast Cancer Study Group
99. HER-2/neu gene amplification characterized by fluorescence in situ hybridization: Poor prognosis in node-negative breast carcinomas
100. Prognostic significance of c-erbB-2/neu amplification and epidermal growth factor receptor (EGFR) in primary breast cancer and their relation to estradiol receptor (ER) status
101. ERBB2 gene amplification detected by fluorescent differential polymerase chain reaction in paraffin-embedded breast carcinoma tissues
102. Correlation between c-erbB-2 amplification and risk of recurrent disease in nodenegative breast cancer
103. HER-2/neu gene amplification by fluorescence in situ hybridization allows risk-group assessment in node-negative breast cancer
104. Predictive value of c-erbB-2 and cathepsin-D for Greek breast cancer patients using univariate and multivariate analysis
105. Follow-up study of HER-2/neu amplification in primary breast cancer
106. Amplification of c-erbB-2, int-2 and c-myc genes in node-negative breast carcinomas: Relationship to prognosis
107. Utility of c-erbB-2 in tissue and in serum in the early diagnosis of recurrence in breast cancer patients: Comparison with carcinoembryonic antigen and CA15.3
108. C-erbB-2 oncoprotein in the sera and tissue of patients with breast cancer: Utility in prognosis
109. A tumor marker utility grading system (TMUGS): A framework to evaluate clinical utility of tumor markers
110. The prognostic significance of c-erbB-2 serum protein in metastatic breast cancer
111. Elevated serum c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer
112. Prediction of response to antiestrogen therapy in advanced breast cancer patients by pretreatment circulating levels of extracellular domain of the HER-2/c-neu protein
113. Correlation of circulating c-erbB-2 extracellular domain (HER-2) with clinical outcome in patients with metastatic breast cancer
114. Elevated soluble c-erbB-2 antigen levels in the serum and effusions of a proportion of breast cancer patients
115. Elevated circulating HER-2/neu related protein (NRP) is associated with poor survival in patients with metastatic breast cancer
116. Influence of circulating c-erbB-2 serum protein on response to adjuvant chemotherapy in node-positive breast cancer patients
117. The role of ERBB2 extracellular domain in predicting response to chemotherapy in breast cancer patients
118. Serial serum c-erbB-2 levels in patients with breast cancer